Aoife Brennan/LinkedIn
Jun 12, 2026, 14:27
Aoife Brennan: Ongoing Budo Study Demonstrates Potential in Challenging ITP Population
Aoife Brennan, Board Member at Critical Path Institute (C-Path), President and CEO of Climb Bio, shared a post on LinkedIn:
“Delighted to share data from our ongoing study of budo in ITP today at EHA.
Many of the patients enrolled had a higher number of prior lines of therapy than baseline platelet count which illustrates the need for new treatments that provide durable treatment response.
Immense gratitude to the patients and investigators who are participating and congratulations to the team Climb Bio.”
Stay updated with Hemostasis Today.
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters
-
Oct 28, 2026, 13:13Michael Cahillane: Three-Buffy-Coat Platelets – Strengthening Blood Supply Resilience
-
Oct 28, 2026, 13:05N. Mariana S. Vasquez: Antiplatelets vs Anticoagulants – Key Clinical Differences
-
Oct 28, 2026, 12:45Panithaya Chareonthaitawee: A Podcast Walk Through Anticoagulation
-
Oct 28, 2026, 11:55Natalia C. Badillo: Anticoagulation in AF – A Decision Beyond the Score